Trial Profile
Phase 4 Study of Nasea(R)/Ramosetron Inj.as Anti-emetics in the Patients Undergoing Facial Bone Fracture Operations
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ramosetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Therapeutic Use
- 10 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 18 Nov 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
- 18 Nov 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov record.